What constitutes high-risk locally advanced prostate cancer?

Clinical Genitourinary Cancer

Volumn 4, Issue 3, 2005, Pages 193-196

  Mannuel, Heather D ^a,b   Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

External beam radiation therapy; Gleason score; Prostate specific antigen; Radical prostatectomy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; BLOOD; MALE; PATHOLOGY; PROSTATE TUMOR;

HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 33644955453     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.032     Document Type: Review

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Murphy GP, Nataraja N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127:928.
3. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughn ED, eds. Campbell's Urology. Philadelphia: WB Saunders; 1992:1159-1221.
4. Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual. New York: Springer-Verlag; 2002:310.
5. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-114.
6. Catalona WJ, Smith DS, Ortnstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452-1455.
7. Rietbergen JB, Hoedemaeker RF, Kruger AE, et al. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161:1192-1198.
8. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143:747-752.
9. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58:843-848.
10. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28:555-565.
11. Merrick GS, Butler WM, Galbreath RW, et al. Biochemical outcome for hormone-naïve patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002; 60:98-103.
12. Herman CM, Kattan MW, Ohori M, et al. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001; 25:657-660.
13. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54:1058-1063.
14. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9:6357-6362.
15. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21:1715-1721.
16. Dattoli M, Wallner K, True L, et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999; 45:853-856.
17. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer 2003; 97:979-983.
18. Straub B, Muller M, Krause H, et al. Molecular staging of surgical margins after radical prostatectomy by detection of telomerase activity. Prostate 2001; 49:140-144.
19. Sciarra A, Voria G, Monti S, et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 2004; 58:421-428.
20. Aaltomaa S, Lipponen P, Ala-Opas M, et al. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 1999; 80:477-482.
21. Chu LW, Troncoso P, Johnston DA, et al. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 2003; 36:303-312.
22. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-945.
23. Medeiros RM, Morais A, Vasconcelos A, et al. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002; 8:3433-3437.
24. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-114.
25. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-1451.
26. Khan MA, Partin AW. Partin tables: past and present. BJU 2003; 92:7-11.
27. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology 2001; 58:843-848.
28. Blute ML, Bergsrtalh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 165:1591-1595.
29. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771.
30. Kattan MW, Wheeler TH, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507.
31. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1642-1645.
32. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17:168-172.
33. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18:3352-3359.